Their argument seems to be that we have 2 months of evidence that hospitalizations & negative effects are strongly reduced even by single doses, and we can reduce world-wide virus numbers by getting more 2x single dose resistances rather than single person double doses.
In this view, the risk of resistant strains would actually be less with 2 people at ~85% resistance, than one person with 95%. This is because if everyone had 85% resistance the virus reproduction rate would be <1, and it would completely die out, so wouldn't have an opportunity to evolve stronger strains - which it currently does have due to being prevalent all over the world.
When vaccines are in limited supply, expanding the number of people who receive some vaccine can reduce disease and mortality compared to concentrating vaccines in a subset of the population. A corollary of such dose-sparing strategies is that vaccinated individuals may have less protective immunity. Concerns have been raised that expanding the fraction of the population with partial immunity to SARS-CoV-2 could increase selection for vaccine escape variants, ultimately undermining vaccine effectiveness. We argue that although this is possible, preliminary evidence instead suggests such strategies should slow the rate of vaccine or immune escape. As long as vaccination provides some protection against escape variants, the corresponding reduction in prevalence and incidence should reduce the rate at which new variants are generated and the speed of adaptation. Because there is little evidence for efficient immune selection of SARS-CoV-2 during typical infections, these population-level effects are likely to dominate vaccine-induced evolution.i.e. if you think 1x0%, 1x95% is better than 2x85%, do you not also think that 3x0%, 1x99% is better?